Carboplatin Injection Clinical Trials
8 recruitingDrug
Phase 34Phase 23Phase 12
Showing 1–8 of 8 trials
Recruiting
Phase 2
SKB500 Combinations in Patients With Small Cell Lung Cancer
Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.80 enrolled1 locationNCT07296809
Recruiting
Phase 1Phase 2
A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
Advanced Neuroendocrine Carcinoma
Nanjing Leads Biolabs Co.,Ltd178 enrolled25 locationsNCT06157827
Recruiting
Phase 3
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
NSCLC Patients With Brain Metastasis
Allist Pharmaceuticals, Inc.380 enrolled1 locationNCT06970639
Recruiting
Phase 3
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR
Allist Pharmaceuticals, Inc.300 enrolled2 locationsNCT06956001
Recruiting
Phase 2
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Advanced Solid Tumour
Nanjing Leads Biolabs Co.,Ltd230 enrolled24 locationsNCT06783647
Recruiting
Phase 3
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
Advanced Cervical Cancer
Shanghai Shengdi Pharmaceutical Co., Ltd720 enrolled1 locationNCT07168200
Recruiting
Phase 1
Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer
Widespread Small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.48 enrolled1 locationNCT07009457
Recruiting
Phase 3
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc416 enrolled1 locationNCT06792253